RCUS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RCUS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Arcus Biosciences's Enterprise Value is $456.7 Mil. Arcus Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-225.0 Mil. Therefore, Arcus Biosciences's EV-to-EBIT ratio for today is -2.03.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Arcus Biosciences's Enterprise Value is $456.7 Mil. Arcus Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-216.0 Mil. Therefore, Arcus Biosciences's EV-to-EBITDA ratio for today is -2.11.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Arcus Biosciences's Enterprise Value is $456.7 Mil. Arcus Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $237.0 Mil. Therefore, Arcus Biosciences's EV-to-Revenue ratio for today is 1.93.
The historical data trend for Arcus Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Enterprise Value | Get a 7-Day Free Trial | 275.57 | 976.97 | 2,482.42 | 501.57 | 694.05 |
Arcus Biosciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Enterprise Value | Get a 7-Day Free Trial | 379.34 | 583.10 | 553.66 | 694.05 | 731.60 |
For the Biotechnology subindustry, Arcus Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Arcus Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1442.05 | + | 0 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 11 | + | 0 | - | 759 |
= | 694.1 |
Arcus Biosciences's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as
Enterprise Value (Q: Mar. 2024 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1715.59728 | + | 0 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 11 | + | 0 | - | 995 |
= | 731.6 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences (NYSE:RCUS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Arcus Biosciences's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 456.696 | / | -225 | |
= | -2.03 |
Arcus Biosciences's current Enterprise Value is $456.7 Mil.
Arcus Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-225.0 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Arcus Biosciences's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 456.696 | / | -216 | |
= | -2.11 |
Arcus Biosciences's current Enterprise Value is $456.7 Mil.
Arcus Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-216.0 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Arcus Biosciences's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 456.696 | / | 237 | |
= | 1.93 |
Arcus Biosciences's current Enterprise Value is $456.7 Mil.
Arcus Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $237.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Arcus Biosciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Goeltz Ii Robert C. | officer: Chief Financial Officer | 343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080 |
Juan C. Jaen | director, 10 percent owner, officer: President | 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
Jennifer Jarrett | officer: See Remarks | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Alexander Azoy | officer: Chief Accounting Officer | 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362 |
Gilead Sciences Inc | 10 percent owner | 333 LAKESIDE DR, FOSTER CITY CA 94404 |
Terry J Rosen | director, 10 percent owner, officer: Chief Executive Officer | C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080 |
Carolyn C. Tang | officer: General Counsel | 3928 POINT EDEN WAY, HAYWARD CA 94545 |
Dimitry Sa Nuyten | officer: Chief Medical Officer | 740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710 |
Linda Slanec Higgins | director | 3610 LOUIS RD., PALO ALTO CA 94303 |
Nicole Lambert | director | 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116 |
William Grossman | officer: Chief Medical Officer | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Yasunori Kaneko | director, 10 percent owner | 509 ROEHAMPTON, HILLS BOROUGH CA 94010 |
Kathryn E Falberg | director | C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Michael Quigley | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Andrew J Perlman | director | 618 MIRADA AVE, STANFORD CA 94305 |
From GuruFocus
By Business Wire • 11-13-2023
By Business Wire Business Wire • 04-25-2023
By Business Wire • 10-10-2023
By Business Wire Business Wire • 06-09-2023
By Business Wire Business Wire • 04-11-2023
By Business Wire • 09-26-2023
By Business Wire • 06-26-2023
By Business Wire Business Wire • 02-24-2023
By Business Wire • 07-25-2023
By Business Wire • 08-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.